uniQure Stock Plunges 49% on FDA Gene Therapy Setback; Class Action Lawsuit Filed

$QURE shareholders facing significant losses have a critical deadline approaching: Pomerantz Law Firm has filed a securities class action lawsuit against uniQure N.V. stemming from a devastating regulatory setback that triggered a 49.34% stock decline. The lawsuit centers on alleged securities fraud related to undisclosed or misrepresented information surrounding the company's lead pipeline asset, AMT-130, a gene therapy candidate for Huntington's disease. Investors who suffered losses have until April 13, 2026, to join the litigation as lead plaintiffs, marking a crucial window for affected shareholders to participate in potential recoveries.

The FDA Feedback and Stock Collapse

The catalyst for the lawsuit emerged on November 3, 2025, when $QURE received critical feedback from the U.S. Food and Drug Administration (FDA) regarding AMT-130's clinical development program. The regulatory feedback proved far more damaging than the market had anticipated, triggering an immediate and severe equity correction:

• Stock decline: 49.34% plunge following FDA feedback announcement
• Trigger date: November 3, 2025
• Drug candidate affected: AMT-130, a gene therapy for Huntington's disease
• Regulatory body: U.S. Food and Drug Administration
• Class action deadline: April 13, 2026, for lead plaintiff claims

This magnitude of decline suggests the FDA feedback contained material negative information that contradicted prior market expectations or company disclosures. Gene therapy programs represent enormous value for biotechnology companies, and negative regulatory feedback can substantially impair future revenue projections and clinical viability assessments.

Market Context and Sector Implications

The $QURE situation unfolds within a challenging environment for gene therapy companies and specialty biotechnology firms. The biotech sector has experienced increased regulatory scrutiny regarding clinical efficacy data, manufacturing capabilities, and risk-benefit profiles for advanced therapies.

uniQure N.V. operates in the gene therapy space, a segment that has experienced both remarkable promise and significant setbacks in recent years. The company's AMT-130 represented a key asset in the pipeline—therapeutic interventions for Huntington's disease represent substantial market opportunities given the disease's severity and limited treatment options. However, the FDA's feedback suggests potential concerns about:

• Clinical trial design or data integrity
• Safety or efficacy endpoints
• Manufacturing and scale-up capabilities
• Risk-benefit assessment relative to competitive alternatives

For investors in specialized biotechnology firms, this case exemplifies the concentrated risk inherent in companies dependent on limited pipeline assets. The 49% decline reflects the market's rapid repricing of uniQure's enterprise value once confidence in AMT-130's regulatory path deteriorated significantly.

Alleged Securities Fraud Claims

Pomerantz Law Firm's class action lawsuit alleges that uniQure failed to disclose material information or made materially false statements regarding AMT-130's development status, regulatory feedback likelihood, or clinical trial trajectory. The firm specializes in complex securities litigation and typically pursues cases involving alleged misrepresentations to investors.

The lawsuit framework typically alleges that shareholders were harmed when:

• Company statements about the drug candidate proved materially inaccurate
• Material negative information was withheld from public disclosures
• The stock price was artificially inflated based on incomplete or misleading information
• The November 3, 2025, FDA feedback revealed the true condition of the program

Investors joining as named plaintiffs in class action securities litigation pursue damages on behalf of all shareholders who purchased $QURE stock during the alleged fraud period. Recoveries, if achieved, typically compensate investors for inflated purchase prices and losses incurred.

Investor Implications and Market Considerations

For $QURE shareholders, this development carries several critical implications:

Capital Preservation: Shareholders who sustained losses should understand that class action participation represents one potential avenue for partial recovery, though outcomes are inherently uncertain and depend on litigation success and ultimate settlement or judgment values.

Valuation Reassessment: The 49% decline suggests the market's confidence in company management and governance practices may have diminished substantially. Investors must reassess whether remaining uniQure assets or pipeline candidates can generate sufficient future value to justify continued investment.

Liquidity and Solvency: Biotechnology companies dependent on external funding may face increased capital-raising challenges following major regulatory setbacks. Investors should monitor announcements regarding financing activities or strategic alternatives.

Sector Contagion: Negative outcomes for gene therapy programs can impact investor sentiment across the entire speciality biotech sector, potentially affecting valuations for other companies with similar regulatory dependencies.

Litigation Timeline: The April 13, 2026, deadline for lead plaintiff claims represents a hard stop for investors seeking to participate in the litigation. Shareholders must act within this window through experienced securities counsel to preserve their claims.

Looking Forward

The uniQure situation underscores the binary nature of biotechnology investing, where single regulatory decisions can fundamentally alter shareholder value. While the company may pursue alternative development strategies for AMT-130 or advance other pipeline candidates, the November 3rd FDA feedback has clearly reset market expectations regarding near-term revenue generation and clinical progress.

For affected investors, the Pomerantz Law Firm class action represents a structured mechanism to pursue potential damages, though successful recovery depends on proving materiality of alleged misstatements and establishing causation between regulatory feedback and subsequent losses. Shareholders should consult experienced securities counsel regarding their eligibility and options before the April 13, 2026 deadline expires. The case will likely influence how market participants evaluate disclosure practices and regulatory risk management at other specialty pharmaceutical and gene therapy companies moving forward.